| http://www.w3.org/ns/prov#value | - The information reported above show there is an increased risk during the first 6 weeks of therapy for patients on NVP compared to patients not on NVP --maintain increased clinical and laboratory surveillance in the following groups: HCV & HBV coinfected patients; patients with elevated baseline ALT/AST >2.5 to 5x ULN --discontinue NVP permanently for ant symptomatic hepatic event (consistent with
|
